2552
C. Kikuchi et al. / Bioorg. Med. Chem. Lett. 12 (2002) 2549–2552
11. To, Z. P.; Bonhaus, D. W.; Eglen, R. M.; Jakeman, L. B.
Br. J. Pharmacol. 1995, 115, 107.
21. Takatani, M.; Sugiyama, Y.; Tozawa, R.; Hamamura, K.
Patent WO9611201, 1996; Chem. Abstr. 1996, 125, 114578.
22. Frankel, S.; Zeimer, K. Biochem, Z. 1920, 110, 234.
23. Nakano, J.; Fukui, H.; Ryu, H.; Senda, N.; Iwatani, W.;
Sakata, Y.; Aryoshi, T. Patent JP06073056, 1994; Chem.
Abstr. 1994, 121, 157661.
24. Matsumura, T.; Hirai, Y.; Nakamoto, M.; Sasaki, T.;
Yokozuka, A.; Shinohara, T. Patent JP63002992, 1988;
Chem. Abstr. 1988, 109, 110409.
25. The order of aromaticity of these compounds is benzene
>thiophene >furan: Fringuelli, F.; Marino, G.; Taticchi, A.;
Grandolini, G. J. Chem. Soc., Perkin Trans. 2 1974, 332.
26. The cyclohexylpiperazine derivative did not show affinity
for the 5-HT7 receptor. See refs 18 and 19.
12. Gustafson, E. L.; Durkin, M. M.; Bard, J. A.; Zgombick,
J.; Branchek, T. A. Br. J. Pharmacol. 1996, 117, 657.
13. Branchek, T. A.; Gustafson, E. L.; Durkin, M. M.; Bard,
J. A.; Weinshank, R. L. Br. J. Pharmacol. 1994, 112, 100P.
14. Sleight, A. J.; Carolo, C.; Petit, N.; Zwingelstein, C.;
Bourson, A. Mol. Pharmacol. 1995, 47, 99.
15. Sumova, A.; Maywood, E. S.; Selvage, D.; Ebling, F. J. P.;
Hastings, M. H. Brain Res. 1996, 709, 88.
16. Ying, S.-W.; Rusak, B. Brain Res. 1997, 755, 246.
17. Schwartz, W. J. Adv. Int. Med. 1993, 38, 81.
18. Kikuchi, C.; Nagaso, H.; Hiranuma, T.; Koyama, M.
J. Med. Chem. 1999, 42, 533.
19. Kikuchi, C.; Ando, T.; Watanabe, T.; Nagaso, H.; Okuno,
M; Hiranuma, T.; Koyama, M. J. Med. Chem. 2002, 45, 2197.
20. New compounds were characterized by 1H NMR and
MS. 2a-[4-(4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-5-yl)butyl]-
2a,3,4,5-tetra-hydrobenz[cd]indol-2(1H)-one (5d): 1H NMR
(CDCl3) d 1.03–1.16 (1H, m), 1.29–1.41 (2H, m), 1.41–1.56
(2H, m), 1.77–1.93 (3H, m), 2.06–2.20 (2H, m), 2.38–2.50 (2H,
m), 2.59–2.73 (3H, m), 2.79–2.89 (3H, m), 3.48 (2H, s), 6.66–
6.69 (2H, m), 6.79 (1H, d, J=7.8 Hz), 7.04 (1H, d, J =5.1
Hz), 7.11 (1H, dd, J=7.6 Hz), 8.00 (1H, br s); EIMS m/z 366
(M+). 1-Methyl-2a-[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-
5-yl)butyl]-2a,3,4,5-tetrahydrobenz[cd]indol-2(1H)-one (5h):
1H NMR (CDCl3) d 0.95–1.07 (1H, m), 1.14–1.33 (2H, m),
1.39–1.53 (2H, m), 1.74–1.94 (3H, m), 2.07–2.19 (2H, m),
2.36–2.47 (2H, m), 2.59–2.72 (3H, m), 2.81–2.91 (3H, m), 3.17
(3H, s), 3.47 (2H, s), 6.63 (1H, d, J=7.6 Hz), 6.69 (1H, d,
J =5.1 Hz), 6.82 (1H, d, J=7.8 Hz), 7.05 (1H, d), 7.17 (1H,
dd); TSPMS m/z 381 (M+H+).
27. This result is different from that in the case of the,
N-methyltetrahydrobenzindole analogue of compound 1,
which is 10-fold less potent than compound 1. See ref 19.
28. Zhang, M.-R.; Haradahira, T.; Maeda, J.; Okauchi, T.;
Kida, T.; Obayashi, S.; Suzuki, K.; Suhara, T. J. Label.
Compd. Radiopharm. In press.
29. Leysen, J. E.; Niemegeers, C. J. E.; Van Nueten, J. M.;
Laduron, P. M. Mol. Pharmacol. 1982, 21, 301.
30. Martin, G. R.; Humphrey, P. P. A. Neuropharmacology
1994, 33, 261.
31. Hoyer, D.; Engel, G.; Kalkman, H. O. Eur. J. Pharmacol.
1985, 118, 13.
32. Lummis, S. C. R.; Sepulveda, M. I.; Kilpatrick, G. J.;
Baker, J. Eur. J. Pharmacol. 1993, 243, 7.
33. Grossman, C. J.; Kilpatrick, G. J.; Bunce, K. T. Br. J.
Pharmacol. 1993, 109, 618.
34. Monsma, F. J., Jr.; Shen, Y.; Ward, R. P.; Hamblin,
M. W.; Sibley, D. R. Mol. Pharmacol. 1993, 43, 320.